Ibopamine: D1-dopaminergic agonist in the diagnosis of glaucoma.

Abstract

PURPOSE:

The purpose of the study was to assess the effect of ibopamine (3,4 di-isobutyrrylester of N-methyldopamine), a D1-dopamine agonist, on intraocular pressure (IOP) in offspring of parents with primary openangle glaucoma as a consequence of outflow structures impairment.

MATERIALS AND METHODS:

We included participants aged between 8 and 40 years: group 1, 163 offspring of at least 1 parent with primary openangle glaucoma with normal IOP and without glaucomatous damages; group 2, 108 offspring of healthy parents (without history or existing glaucoma). Ibopamine test was performed by instilling 2 drops, 5 minutes apart, in both eyes followed by repeated IOP measurements over a 45-minute period. The test is considered positive if there is an IOP increase of ≥3 mm Hg 45 minutes after instillation.

RESULTS:

Baseline IOP before the test was 15.73±2.31 and 15.31±1.86 mm Hg in groups 1 and 2, respectively. Test was positive in 44.33% of cases in group 1 with a mean increase in IOP of 5.57 mm Hg (P<0.001), whereas in all participants of group 2 the test was negative with even 1 to 2 mm Hg IOP reduction.

CONCLUSIONS:

D1-dopaminergic stimulation due to ibopamine increases IOP as a result of increased production of the aqueous humor in participants with an impaired outflow. The study showed that offspring of at least 1 parent with primary openangle glaucoma--offspring without glaucomatous damages--show an increase of IOP after ibopamine administration, which signifies an impaired function of outflow structures and, therefore, a predisposition to intraocular hypertension and possible glaucoma.

• Authors: Michele Virno, Roberto Sampaolesi, Josè Pecori Giraldi, Fabio De Gregorio, Maurizio Taloni, Paolo Brusini, Silvio Di Staso, Gaetano Stecchi
• Journal: Journal of glaucoma (J Glaucoma) Vol. 22 Issue 1 Pg. 5-9 (Jan 2013) ISSN: 1536-481X [Electronic] United States
• PMID: 21946546 (Publication Type: Journal Article)

Chemical References

• DRD1 protein, human
• Dopamine Agonists
• Ophthalmic Solutions
• Receptors, Dopamine D1
• ibopamine
• Deoxyepinephrine

Topics

• Adolescent
• Adult
• Child
• Deoxyepinephrine (adverse effects, analogs & derivatives)
• Dopamine Agonists (adverse effects)
• Female
• Glaucoma, Open-Angle (diagnosis)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Ophthalmic Solutions
• Receptors, Dopamine D1 (agonists)
• Tonometry, Ocular
• Young Adult